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Abstract
 
T cells are activated by binding of the T cell receptor (TCR) to a peptide-major histocompati-
bility complex (MHC) complex (pMHC) expressed on the surface of antigen presenting cells.
Various models have predicted that activation is limited to a narrow window of affinities (or
dissociation rates) for the TCR–pMHC interaction and that above or below this window, T
cells will fail to undergo activation. However, to date there have not been TCRs with suffi-
ciently high affinities in order to test this hypothesis. In this report we examined the activity of
 
a CD8-negative T cell line transfected with a high affinity mutant TCR (K
 
D
 
 
 
 
 
 10 nM) derived
from cytotoxic T lymphocyte clone 2C by in vitro engineering. The results show that despite a
300-fold higher affinity and a 45-fold longer off-rate compared with the wild-type TCR, T
cells that expressed the mutant TCRs were activated by peptide. In fact, activation could be
detected at significantly lower peptide concentrations than with T cells that expressed the wild-
type TCR. Furthermore, binding and functional analyses of a panel of peptide variants sug-
gested that pMHC stability could account for apparent discrepancies between TCR affinity
and T cell activity observed in several prior studies.
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Introduction
 
The 
 
 
 
/
 
 
 
 TCR recognizes a peptide bound to a product of
the MHC. This recognition is programmed during thymic
development, where a T cell will die if it does not bear a
TCR that binds to a self peptide/MHC ligand or if it binds
too tightly. These processes, known as positive and nega-
tive selection, yield a T cell repertoire that is MHC re-
stricted but not self-reactive. That is, T cells must recog-
nize only peptides that are bound to MHC molecules
(rather than free peptides) and must have the potential to
recognize only those peptides that appear “foreign”. “For-
eignness” can be defined as either a difference in structure
compared with the repertoire of normal self peptides or as a
change in the level of the peptide that is present normally.
 
It has been shown that TCR–peptide-MHC (pMHC)
binding affinities that distinguish the processes of positive
selection and T cell activation exhibit an extremely narrow
 
window (1). For example, affinities with K
 
D
 
 values of
 
 
 
100 
 
 
 
M appear to be sufficient to deliver signals for pos-
itive selection, while affinities with K
 
D
 
 values of 1–10 
 
 
 
M
elicit either negative selection or activation of peripheral T
cells (2). It has been suggested that it is the affinity of a
TCR–pMHC interaction (3) or the dissociation rate of the
TCR from the pMHC (4, 5) that determines the biologi-
cal activity of a T cell. In the “kinetic proofreading
model,” it has been proposed that TCR–pMHC lifetimes
of dissociation (t
 
1/2
 
) in the range of 
 
 
 
10 to 40 s yield full
signaling and T cell activation, while shorter lifetimes yield
partial signaling and antagonist effects (6–8). Lanzavecchia
and colleagues have shown that a single pMHC complex
appears to engage and downregulate up to 100 TCR mol-
ecules per T cell in a process they refer to as “serial trigger-
ing” (9). This serial triggering of TCRs has been proposed
to be important in optimal signaling of the T cell. Based
on this and the kinetic model it has been suggested that
long lifetimes of dissociation might prevent serial trigger-
ing and thus signaling. It has also been proposed that a
TCR–pMHC interaction might reach an “affinity ceil-
ing,” above which there is no advantage for the T cell
(10). This proposition was based largely on analysis of the
2C system, where the TCR has the highest measured af-
finity for a pMHC, the alloantigen QL9/L
 
d
 
 (K
 
D
 
 
 
 
 
0.1 
 
 
 
M
to 3 
 
 
 
M depending on the type of measurement; refer-
ences 11 and 12). Only a few QL9/L
 
d
 
 complexes appeared
to be necessary to trigger the 2C T cell and hence it is dif-
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ficult to reconcile how a higher affinity TCR could be
even more effective (13).
The models described above predict that TCR affinities
above a particular threshold will be detrimental to T cell
activity or, at the least, will not yield an improvement in
pMHC sensitivity. Potentially related to these possibilities,
there have been a number of examples of T cells that have
TCRs with higher affinity or slower off-rates for a pMHC,
yet they exhibited reduced activity for the pMHC (1, 14–
16). Of particular note is a recent study that examined two
different class I–reactive T cell systems to support the no-
tion that higher affinity (slower off-rates) for a pMHC
yielded reduced activity (17). These studies were limited in
that the affinities and off-rates reside within the narrow
range that is typical of in vivo-selected T cell clones (i.e.,
K
 
D
 
 values that are in the micromolar range, with lifetimes
of 10 to 40 s; reference 18).
To address this issue more conclusively, we have exam-
ined the activity of a T cell that expresses a TCR with 100-
fold greater affinity than even the highest affinity interac-
tion yet studied, the 2C TCR and QL9/L
 
d
 
. The study was
made possible by using the m6 mutant TCR from CTL 2C
(K
 
D
 
 
 
 
 
 10 nM) that was engineered for higher affinity by a
process of yeast surface display and directed evolution (19).
The m6 mutant contains identical V
 
 
 
 and V
 
 
 
 regions as
the 2C TCR except for the tip of the CDR3
 
 
 
 loop, which
differs at five contiguous residues between m6 (HQGRY)
and 2C TCR (GFASA). T cell hybridomas transfected
with the m6 or wt TCR were compared for IL-2 release
and TCR downregulation over a range of concentrations
of QL9 and QL9 variants. The variants were selected based
on their different binding affinities for the TCRs (as a pep-
tide/L
 
d
 
 complex) and for their differences in binding to and
stabilization of L
 
d
 
. The findings indicate that: even with an
affinity as high as 10 nM and a dissociation lifetime of 1,650 s,
T cells exhibited enhanced, peptide-specific activity. This
suggests that the kinetic or equilibrium “optimum” models
need to be revised. We also observed that a peptide/L
 
d
 
complex (p2Ca/L
 
d
 
) that displayed high affinity for the m6
TCR yielded lower activity than might be predicted from
the affinity. Evidence indicated that this reduced biological
activity could be accounted for by the instability of the
pMHC complex over the period of the assay. We propose
that the analogous “aberrant” behavior (between TCR–
pMHC affinity and activity) observed in various systems
might be explained by pMHC stability differences, espe-
cially over the course of relatively long T cell activation
assays.
 
Materials and Methods
 
Peptides.
 
MCMV (YPHFMPTNL), p2Ca (LSPFPFDL), QL9
(QLSPFPFDL), and QL9 variant peptides were synthesized by
standard F-moc chemistry at the Protein Sciences Facility at the
University of Illinois, Urbana, IL, and were purified by C-18 re-
verse-phase HPLC using a linear acetonitrile gradient. Peptide
purity and concentration were determined by quantitative amino
acid analysis.
 
mAbs.
 
KJ16 is a rat IgG mAb that is specific for the mouse
V
 
 
 
8.1 and V
 
 
 
8.2 regions of the TCR. F23.1 is a mouse IgG2a
mAb that binds to the mouse V
 
 
 
8.1, 8.2, and 8.3 regions. F23.2
is a mouse IgG1 mAb that is specific for the mouse V
 
 
 
8.2 re-
gion. 30–5-7 is a mouse IgG2a mAb that binds to the 
 
 
 
2 domain
of the mouse MHC molecule, L
 
d
 
. Abs were purified from ascites
or culture supernatants.
 
Peptide–MHC Production.
 
The J558L hybridoma that ex-
presses the L
 
d
 
/IgG1 fusion was provided by Dr. Sean O’Herrin,
University of Chicago, Chicago, IL (20). Cells were grown in
serum-free hybridoma media (GIBCO BRL) until they reached
 
 
 
60–70% viability. Supernatants were then harvested, filtered
(0.45 
 
 
 
m), and concentrated in a stirred-cell concentrator (Ami-
con; 10,000 dalton molecular weight cut-off). Proteins were
precipitated in 50% saturated ammonium sulfate, resuspended in
50 mM K
 
2
 
HPO
 
4
 
, pH 7.7, and purified by gel filtration HPLC
(G-200; Amersham Pharmacia Biotech). Appropriate fractions
were pooled, concentrated, and exchanged into peptide loading
buffer (130 mM citrate, 150 mM NaCl, 124 mM Na
 
2
 
HPO
 
4
 
, pH
6.5). Specific peptides were loaded by incubating L
 
d
 
/Ig at 37
 
 
 
C
for 1.5 h in the presence of 100-fold molar excess of peptide. Af-
ter incubation, the pH was adjusted to 7.4 with 1.0 M Tris, pH
9.0, and the complexes were allowed to refold at 4
 
 
 
C for 24 h.
Purity was assessed by SDS-PAGE. Peptide-loaded complexes
were purified a second time by G-200 HPLC immediately be-
fore use in BIAcore experiments.
 
Soluble TCR Production.
 
The pRMHa-3 
 
Drosophila
 
 expres-
sion plasmids containing the 2C 
 
 
 
 and 
 
 
 
 chains (with the trans-
membrane regions deleted) were provided by Dr. Luc Teyton,
The Scripps Research Institute, La Jolla, CA (12). The 2C
CDR3
 
 
 
 was mutated to the m6 CDR3
 
 
 
 by a two-step Quick-
change method (Stratagene). The m6 
 
 
 
 and 2C 
 
 
 
 pRMHa-3
plasmids were cotransfected together with a plasmid conferring
G418 resistance (pUChsNEO) into SC2 
 
Drosophila melanogaster
 
cells by Ca
 
3
 
(PO
 
4
 
)
 
2
 
 precipitation (19:19:1 ratio 
 
 
 
:
 
 
 
:NEO). Stable
transfectants were selected and maintained at 27
 
 
 
C in Schneider’s
complete media (GIBCO BRL) containing 1 mg/ml G418.
TCR expression was induced by the addition of CuSO
 
4
 
 to a final
concentration of 500 
 
 
 
M. Supernatants were harvested after 3 d,
concentrated, and dialyzed against PBS, pH 8.0. His
 
6
 
-tagged
TCRs were isolated by native nickel affinity chromatography us-
ing a 5 ml Ni-NTA agarose (QIAGEN) column. Appropriate
fractions were pooled, concentrated and purified further by gel
filtration HPLC.
 
Peptide–MHC Binding Assays.
 
T2-L
 
d
 
 is a human lymphoblas-
toid line transfected with the L
 
d
 
 heavy chain (21). To monitor
TCR binding to cell-bound peptide/L
 
d
 
, T2-L
 
d
 
 cells (
 
 
 
3 
 
  
 
10
 
6
 
/
ml) were incubated with purified peptides (
 
 
 
1–10 
 
 
 
M final con-
centration) at 37
 
 
 
C for 2 h. Cells were washed with PBS contain-
ing 1% BSA (PBS/BSA) and stained for 30 min on ice with 2C
or m6 TCR 
 
Drosophila
 
 supernatants. Cells were washed with
PBS/BSA and bound TCR was detected with biotinylated F23.1
IgG (F23.1:biotin) followed by streptavidin:phycoerythrin (SAv:
PE; BD PharMingen). Cellular fluorescence was measured by
flow cytometry on a Coulter Epics XL instrument. To measure
TCR dissociation rates from cell-bound peptide/L
 
d
 
, peptide-
loaded T2-L
 
d
 
 were incubated with m6 TCR supernatants,
washed, and resuspended at room temperature in PBS/BSA con-
taining excess F23.2 IgG (
 
 
 
300 
 
 
 
g/ml) as a competitor. At vari-
ous times, cells were washed with ice cold PBS/BSA, centri-
fuged, and remaining cell-bound m6 TCR was detected with
F23.1:biotin and SAv:PE as described above. Cellular fluores-
cence was measured by flow cytometry. 
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Surface plasmon resonance (SPR)
 
*
 
 measurements were per-
formed on a BIAcore 3000 instrument (BIAcore). Rabbit anti–
mouse IgG was coupled to a CM5 surface through amine chem-
istry. Kinetic experiments were performed by immobilizing
 
 
 
600 RU of QL9/L
 
d
 
/Ig followed by injections of various con-
centrations of purified m6 TCR at a flow rate of 30 
 
 
 
l/min in
PBS at 25
 
 
 
C. Surfaces were regenerated with 10 mM glycine, pH
1.5. Responses were subtracted from a blank surface prepared by
ethanolamine deactivation of the CM5 surface. Response curves
were fitted to a 1:1 Langmuir binding model. TCR binding was
not observed using the null peptide, MCMV/L
 
d
 
/Ig, immobilized
on the chip.
 
T Cell Transfections.
 
Full-length 2C 
 
 
 
 and 2C 
 
 
 
 cDNAs
were cloned into a modified form of the SFFV expression plas-
mid (22). The construct containing the 
 
 
 
 chain also contained a
neomycin resistance gene. The 2C CDR3
 
 
 
 was mutated to the
m6 CDR3
 
 
 
 by a two-step Quickchange procedure (Stratagene).
NotI-linearized plasmids were electroporated at a 1:10 ratio (
 
 
 
:
 
 
 
)
with 5 
 
 
 
 10
 
6 
 
58
 
 
 
/
 
 
 
 cells. 58
 
 
 
/
 
 
 
 (CD4
 
 
 
, CD8
 
 
 
, K
 
b
 
 
 
, L
 
d
 
 
 
), a
variant of the DO-11.10.7 mouse T cell hybridoma, does not ex-
press functional TCR 
 
 
 
 or 
 
 
 
 chains but does express the CD3
subunits (23). Approximately 24 h after transfection, cells were
placed under antibiotic selection (1.5 mg/ml G418) and after 1–3
wk colonies were picked, expanded, and examined for TCR ex-
pression. Initial screening of colonies with F23.1 and F23.2 was
performed in order to isolate transfectants that had approximately
the same level of 
 
 
 
-chain.
 
T Cell Activation Assays.
 
TCR transfectants (7.5 
 
  
 
10
 
4
 
) were
incubated with T2-L
 
d
 
 cells (7.5 
 
  
 
10
 
4
 
) and various concentra-
tions of peptides in 96-well U-bottom plates at 37
 
 
 
C and 5%
CO
 
2
 
. After 30 h, supernatants were harvested and assayed for
IL-2 by ELISA or with the IL-2–dependent cell line HT2 in a
[3H]thymidine uptake assay. To monitor peptide/Ld stability and
CD3/TCR downregulation, cells were stained with m6 TCR
Drosophila supernatants followed by F23.1:biotin (or KJ16:bio-
tin). The final incubation included SAv:PE (BD PharMingen)
to detect F23.1 bound to the surface TCR on transfectants and
the bound m6 TCR on the T2-Ld cells, anti-CD90.2 FITC
(53–2.1, anti–Thy-1.2; BD PharMingen) to detect 58 /  trans-
fectants, and anti–CD3 -cychrome (2C11; BD PharMingen) as a
second marker for TCR/CD3 levels. Cellular fluorescence was
measured by flow cytometry, gating on CD90.2  cells (TCR
transfectants).
To assay IL-2 levels, ELISA plates (Immulon 2 HB; Dynex
Technologies) were coated overnight at 4 C with 2.5  g/ml rat
anti–mouse IL-2 IgG (JES6–1A12; BD PharMingen) in 0.1 M
Na2HPO4, pH 9.0. Plates were washed with PBS-0.05% Tween
20 (PBS-T), blocked with PBS/1% BSA, and undiluted superna-
tants were added and incubated at room temperature for 1 h. Af-
ter washing, plates were incubated with 7  g/ml biotinylated rat
anti–mouse IL-2 IgG (JES6–5H4; BD PharMingen) for 1 h at
room temperature. After washing, streptavidin-horseradish per-
oxidase (HRP; Kirkegaard and Perry Laboratories) was added at a
dilution of 1:10,000 for 30 min. Plates were washed, TMB sub-
strate (Kirkegaard and Perry Laboratories) was added, reactions
were stopped with 1 N H2SO4, and absorbance (450 nm) was
measured. Identical results were obtained when the IL-2–depen-
dent cell line HT2 was used to monitor IL-2 levels in a [3H]thy-
midine uptake assay (data not shown).
Results and Discussion
Peptide/Ld Binding by the m6 Mutant TCR. To draw
more conclusive correlates of affinity (or off-rate) and T
cell activity, we have isolated higher affinity TCRs by a di-
rected evolution strategy (19). In the present study, we
elected to study the mutant m6 that showed the highest af-
finity for QL9/Ld. The m6 TCR was cloned into two dif-
ferent expression systems, yeast and insect, in order to pro-
duce soluble TCR. The yeast secreted m6 single-chain
TCR (scTCR) (V -linker-V ) has been described previ-
ously and exhibited a KD of 9 nM as measured in a compe-
tition assay (19). In this assay, 125I-labeled Fab fragments of
the anti-Ld antibody 30–5-7 were competed for binding by
soluble wild-type (wt) 2C scTCR and m6 mutant scTCR.
To further explore the affinity and kinetics of m6 TCR
binding to various QL9 peptide variants (24), a soluble,
full-length heterodimer of wt and m6 TCR were produced
in  Drosophila cells. The peptide variants included p2Ca
(lacking the NH2-terminal glutamine of QL9), or several
QL9 variants containing position five (Phe) substitutions
(QL9-Y5, QL9-M5, QL9-R5) or position eight (Asp) sub-
stitutions (QL9-E8 and QL9-Q8). Phe5 of QL9 is pre-
dicted to be buried in the C pocket of Ld, (25) and position
5 variants are known to affect both TCR binding and Ld
binding (24). Asp8, on the other hand, is predicted to point
directly toward the TCR, yielding a negatively charged
surface at this position (25). The Ld-binding null peptide
MCMV was used as a control. Soluble m6 and wt TCR
binding was detected by loading the peptides under saturat-
ing conditions onto Ld expressed on the surface of T2-Ld
cells and then incubating cells with the full length TCRs,
followed by F23.1:biotin and SAv:PE. As shown in Fig. 1,
m6 TCR exhibited a range of binding to these peptide-Ld
*Abbreviations used in this paper: pMHC, peptide-MHC complex; SAv:PE,
streptavidin-PE; scTCR, single-chain TCR; SPR, surface plasmon reso-
nance; wt, wild-type.
Figure 1. Soluble TCR binding to cell surface peptide/MHC. T2-Ld
cells were loaded with saturating concentrations of peptides for 2 h at
37 C, washed, and then incubated at room temperature with Drosophila-
expressed soluble 2C or m6 TCR followed by F23.1–SAv:PE. Cellular
fluorescence was measured by flow cytometry. Ld-binding peptides in-
cluded the null peptide MCMV (YPHFMPTNL) and the 2C-reactive
peptides p2Ca (LSPFPFDL), QL9 (QLSPFPFDL), and various QL9 vari-
ants that contained the indicated mutations (e.g., QL9-Y5 contains a Tyr
substitution for the Phe at position 5).1046 High Affinity T Cell Receptors
complexes. The low end of the range (i.e., binding of m6
to QL9-R5/Ld; see inset, Fig. 1) approaches approximately
that of the wt TCR–QL9/Ld interaction whereas the high
end of the range (i.e., binding of m6 to QL9-Y5/Ld) is
slightly improved compared with the m6 TCR–QL9/Ld
interaction. The relative binding among these pMHC was
identical at 4 C, 25 C, and 37 C (data not shown).
To quantitate the binding of m6 TCR to QL9/Ld and to
examine binding kinetics, the m6 TCR–QL9/Ld interac-
tion was measured by surface plasmon resonance using BIA-
core instrumentation. QL9/Ld/Ig was immobilized on an
anti-Ig sensor chip and m6 was injected at various concen-
trations (Fig. 2 A). The association constant (ka) of m6
binding was 4.2   104 (M 1s 1) and the dissociation con-
stant (kd) was 4.2   10 4 (s 1). The corresponding values
for the wt 2C TCR are 0.6   104 (ka in M 1s 1) and 200  
10 4 (kd in s 1), as measured by BIAcore analyses (12).
The affinity constant determined from these kinetic con-
stants was 10 nM for m6, in agreement with the value of 9
nM determined for the m6 scTCR by a completely inde-
pendent method. The affinity of the wt TCR for QL9/Ld
was 3  M based on BIAcore analyses (12) and 1.5  M
based on the competitive inhibition assay described above
(19). Hence, the m6 TCR has approximately a sevenfold
faster on-rate, a 45-fold slower off-rate, and a 300-fold
higher affinity than the 2C wt TCR (Table I). If one com-
pares the TCR–QL9/Ld lifetimes by calculating t1/2 values
(t1/2   ln2/kd), the m6 TCR exhibits a t1/2 of 1,650 s,
compared with that of wt 2C TCR which is 35 s. The life-
times of TCR–pMHC interactions for strong agonists in
several T helper cell systems typically exhibit t1/2 values in
the 10 to 15 s range (2, 5).
Because of the slow dissociation rate, we were also able
to use a flow cytometry–based assay to measure dissociation
of m6 from QL9/Ld and several QL9 variant/Ld complexes
on T2-Ld cells (Fig. 2 B). In these assays, the average disso-
ciation constant (kd) for m6 from QL9/Ld was 8.5   10 4
(s 1), in close agreement with BIAcore data. The average
m6 dissociation constants for QL9-Y5/Ld (5.9 10 4 s 1);
QL9/Ld (8.5 10 4 s  1), p2Ca/Ld (1.2 10 3 s  1), and
QL9-M5/Ld (5.0 10 3 s  1) were completely consistent
with the qualitative binding analysis shown in Fig. 1. The
t1/2 values calculated from these data (QL9/Ld, 830 s; QL9-
Y5/Ld, 1,180 s; p2Ca/Ld, 580 s; QL9-M5/Ld, 140 s) were
all at least 10 times longer than the lifetimes of normal
TCR–pMHC interactions for strong agonists.
Role of Affinity in T Cell Activation. Genes encoding
the 2C  -chain and either the wt   chain or the m6  
chain were cotransfected into the 58 /  T cell hybridoma
that lacks its own    TCR but contains the CD3 subunits
and thus is fully capable of undergoing TCR-mediated ac-
tivation (23). Clones of G418-resistant transfectants from
the 2C wt TCR and m6 TCR were isolated and examined
for TCR surface levels using the V -specific Abs F23.1
and F23.2, which bind to nonoverlapping epitopes. The
clonotypic antibody 1B2 could not be used because the
CDR3  mutations in m6 eliminate binding of this anti-
body. Eight colonies each of wt and m6 TCR that were
positive for F23.2 binding were examined in an IL-2 re-
lease assay at different QL9 concentrations. Clones of wt
and m6 TCRs that exhibited similar levels of TCR as
judged with F23.1 and F23.2 (Fig. 3) and similar levels of
IL-2 release were used in the studies presented. However,
each of the IL-2 releasing isolates of wt TCR and m6
TCR transfectants showed relative peptide dose responses
Figure 2. Kinetics of peptide/Ld binding by soluble, high-affinity
TCR m6. (A) Representative SPR sensorgrams of soluble m6 TCR
binding to QL9/Ld. Experiments were performed by immobilizing QL9/
Ld/Ig by capture with rabbit anti–mouse IgG followed by injections of
purified m6 TCR (900 nM, 400 nM, 200 nM, PBS blank; duplicate runs
shown from top to bottom, respectively). TCR binding to the null pep-
tide, MCMV/Ld/Ig, immobilized on the chip was undetectable (data not
shown). (B) Soluble m6 TCR dissociation from four different cell-bound
peptide/Ld complexes. Peptide-loaded T2-Ld cells were incubated with
full length m6 TCR for 30 min. After washing, cells were resuspended at
room temperature in buffer containing excess competing Ab (F23.2 at
300  g/ml). At various times, cell aliquots were washed and remaining
cell bound m6 TCR was detected by flow cytometry with F23.1–biotin
followed by SAv:PE. Data points were fit with an exponential equation
to determine dissociation rate constants. Representative data is shown for
the peptides QL9 ( ), QL9-Y5 ( ), p2Ca ( ), and QL9-M5 ( ) (inset).
The dissociation rate constants (kd) determined for the m6 TCR and
pMHC ligands were: QL9/Ld, 8.5   10 4 s 1 (n   3); QL9-Y5/Ld,
5.9   10 4 s 1 (n   2); p2Ca/Ld, 1.2   10 3 s 1 (n   3); QL9-M5/Ld,
5.0   10 3 s 1 (n   2). The t1/2 values calculated from these data were:
QL9/Ld, 830 s; QL9-Y5/Ld, 1,180 s; p2Ca/Ld, 580 s; QL9-M5/Ld, 140 s.
MFU, mean fluorescence units.1047 Holler et al.
identical to those described below (data not shown).
F23.1/F23.2  transfectants were also examined for their
ability to bind directly to QL9/Ld/Ig. At the concentration
tested (100 nM; above the KD of m6, but below the KD of
wt), QL9/Ld/Ig binding was detected only with the m6
transfectants (data not shown).
Transfectants were examined in a 30 h IL-2 secretion as-
say in the presence of various peptides and T2-Ld target
cells. As shown in Fig. 4, peptide-specific IL-2 release was
observed for both the wt TCR and m6 TCR lines. How-
ever, the m6 transfectant showed remarkable sensitivity to
the peptides, such that they were stimulated at 10 to 300-
fold lower peptide concentrations than the wt transfectants
(summarized in Table I). This enhanced sensitivity was ex-
hibited for each QL9 variant and it was reproducible among
different lines that were isolated from the wt and m6 trans-
fections (data not shown). Thus, not only were T cells that
expressed the high-affinity TCR active, but they were sur-
prisingly more sensitive to peptide levels. This finding sug-
gests that the concept of an affinity or off-rate optimum
should be revised, at least to the extent of the affinity of the
m6 TCR. It also may indicate that the in vitro engineering
of TCRs for higher affinity could prove useful for increas-
ing the activity of T cells against particular pMHC targets,
for example in adoptive T cell therapies (26).
The serial triggering model suggests that multiple TCRs
on the surface of a T cell can be bound by a single pMHC
complex and that this serial binding leads to enhanced sig-
naling. While TCRs on the m6 transfectants are efficiently
downregulated by pMHC (see below), the longer off-rates
of these interactions would have led to the prediction that
fewer serial triggering events could occur compared with
the wt TCR transfectants. Despite this prediction, the m6
T cells exhibited rapid downregulation of TCRs and en-
hanced activity (see below). These results support the no-
tion that serial triggering is itself unnecessary for T cell ac-
tivity and in fact may be detrimental to it (27–29). What
then is the mechanism by which the m6 T cells are able to
efficiently recognize and be triggered by pMHC? We pro-
pose that the longer lifetimes of TCR–pMHC association
allow for enhanced dimerization or clustering of other
nonliganded TCR complexes with the liganded TCR on
the surface of the T cell. The potential importance of
dimerization in T cell activation has been raised previously
in regard to the restricted orientation of TCR–pMHC in-
teractions (30), and it is discussed further below.
Of course, there are caveats to this study that will need
to be explored further: (a) the findings represent a class I
MHC system and it remains to be seen if class II–reactive T
cells behave in the same manner; (b) the T cells do not ex-
press accessory CD8 molecules, which are known to play
an important role in binding and signaling and have been
shown to differ in their contribution within the 2C system,
depending on whether the ligand is Kb or Ld (31); and (c)
the activity measured is that of cytokine release, whereas
other functions such as proliferation may differ in their re-
sponse. Examination of these issues may help address the
question of why TCRs have not evolved a process of affin-
ity maturation, similar to that of Abs. In this regard, it is
possible that the process of negative selection in vivo might
limit the development of high affinity TCRs (32).
A recent study using TCRs from Kb-reactive T cells
came to the opposite conclusion based on the analysis of
Table I. Summary of TCR–pMHC Binding Constants and Peptide Sensitivity of T Cell Transfectants
aBinding to QL9/Ld
IL-2 sensitization dose (SD50)
(nM)b
2C TCR ka kd KD t1/2 QL9 Y5 E8 M5 p2Ca
(M 1s 1)   104 (s 1)   10 4 nM s
wt 0.6 200 3,000 35 0.9 0.3 6 2 2,000
m6 mutant 4.2 4.2 10 1,650 0.003 0.0008 0.8 0.01 40
aBinding measurements from SPR studies. TCR/pMHC half-lives (t1/2) were calculated using the formula ln 2/kd. wt 2C TCR data are from ref-
erence 12.
bData from peptide titrations of T2-Ld cells incubated with 58 /  transfectants. Sensitization doses (SD50) were calculated as the peptide concentra-
tion that yielded 50% of maximal IL-2 release, by fitting the ascending portions of the IL-2 response curves (Fig. 2). Values reported are the means
of two or three independent experiments, each agreeing to within fourfold.
Figure 3. TCR expression by T cell transfectants. T cell hybridomas
transfected with wt (2C) or high-affinity mutant (m6) TCRs were stained
with biotinylated F23.1 IgG (anti-V 8,  90 nM) or F23.2 IgG (anti-
V 8.2,  130 nM) followed by SAv:PE. Cellular fluorescence was mea-
sured by flow cytometry. Histograms on the left of each panel are trans-
fectants stained with SAv:PE alone.1048 High Affinity T Cell Receptors
several TCR mutants (17). In their study, the mutants had
several fold higher binding avidity than the wt TCR, but
they exhibited reduced biological activities. It is unclear to
us what accounts for this discrepancy, especially since the
affinities of the m6 TCR for virtually all of the pMHC ex-
amined here were orders of magnitude higher than in their
system. A possibility, albeit remote, is that CD8  expressed
by the transfectants in their study, affected the signaling
through the TCR/CD8 complex.
Effect of Peptide/MHC Stability in T Cell Activation. In
the course of studies among different T cell systems, there
have been several notable exceptions to the correlate of bi-
ological activity and affinity/lifetime of the TCR–pMHC
interaction (for a review by Davis, see reference 2). Vari-
ous hypotheses have been suggested to account for these
exceptions, including the possibility that differences in af-
finity might exist at the temperature used for binding mea-
surements (e.g., 25 C) and that used in the T cell assay
(37 C) (24, 33). Other possibilities are that TCRs may un-
dergo conformational changes that impact dimerization
and/or signaling or that other T cell accessory molecules,
like CD8, could play a role in modulating activity (14, 31,
33, 34). The broad range of affinities among the interac-
tions examined here provides a useful system to reexamine
this issue.
The binding of m6 TCR to p2Ca is considerably higher
than the binding of m6 TCR to QL9-R5 and QL9-E8 and
the dissociation rate of the m6 TCR–p2Ca/Ld interaction
is slower than the m6 TCR–QL9-M5/Ld interaction (Fig.
2 B). However, the biological activity of the p2Ca peptide
is 2 to 3 orders of magnitude lower than these peptides
(Fig. 4, and data not shown). Similarly, the m6 TCR binds
much better to p2Ca/Ld than the wt TCR does to QL9/
Ld, but the latter stimulates the wt TCR transfectants an
order of magnitude more efficiently.
The explanation for these differences almost certainly
lies in the stability of these various pMHC complexes.
Peptide p2Ca is  100-fold less stable than QL9 and 300-
fold less stable than the QL9-M5 variant in Ld upregulation
assays (24). This stability can be demonstrated by examin-
ing the amount of appropriate pMHC complex on the T2-
Ld cells that remains at the end of the 30 h IL-2 assay. As
shown in Fig. 5, p2Ca/Ld complexes are not even detect-
able at the highest concentration of peptide tested (1  M),
whereas in a shorter assay as used for the original binding
studies, these complexes are easily detected (Fig. 1). This
contrasts with the QL9-M5 peptide which is detectable at
about the same level as p2Ca in a short assay (Fig. 1) but
remains easily detectable at the end of the 30 h IL-2 assay
(Fig. 5). These results are consistent with the greater persis-
tence of the QL9-M5/Ld complex at lower peptide con-
centrations (e.g., note the relative levels of QL9-M5/Ld,
QL9-Y5/Ld, and QL9/Ld complexes detected at 20 nM
peptide in Fig. 5). Identical results were observed for T2-
Ld cultures incubated with peptides for 30 h in the absence
of T cell transfectants and with anti-Ld Ab used as the de-
tecting agent (data not shown).
Figure 4. IL-2 release by T cell hybridomas transfected with the wt 2C
or high-affinity mutant m6 TCRs. 2C TCR ( ) or m6 TCR ( ) trans-
fectants were incubated with T2-Ld APCs in the presence of various con-
centrations of peptides. After 30 h, supernatants were harvested and as-
sayed for IL-2 by ELISA. Assays were done in triplicate and the mean
A450 value for each concentration is shown. ELISA curves from one rep-
resentative experiment are shown for each peptide and transfectant. IL-2
standard curves demonstrated that an A450 value of 0.3 corresponded to
 1,200 pg/ml IL-2. The null peptide MCMV did not elicit detectable
IL-2 at even the highest concentration tested (1  M).1049 Holler et al.
TCR binding assays used here and elsewhere typically
involve measurements at 25 C and over a time scale of
minutes. In addition, peptide–MHC binding assays to mea-
sure the affinity of a peptide for MHC product are also per-
formed in a shorter time frame. However, biological assays
such as IL-2 release and CTL cytotoxicity assays typically
involve several hours to days and are performed at 37 C.
Thus, the effects of peptide stability can be greatly magni-
fied in a biological assay. The results with p2Ca are a useful
example in this regard. While the comparison of m6–
p2Ca/Ld with m6–QL9-R5/Ld or m6–QL9-M5/Ld may
represent extremes with regard to stability and TCR affin-
ity, the results do emphasize an important point. Minor,
perhaps undetectable, differences in peptide–MHC binding
and stability over a short assay period may still yield signifi-
cant biological effects in long term assays. Thus, we pro-
pose that “apparent” exceptions (1, 14–16) to the positive
correlation between affinity (or off-rate) and biological ac-
tivity can be accounted for by pMHC stability. In the 2C
system, it seems likely that the 100,000-fold difference in
biological activity between dEV8/Kb and SIYR/Kb (35) is
due to the greatly reduced stability dEV8/Kb has compared
with SIYR/Kb (unpublished data). Recent studies have
further emphasized the importance of pMHC stability in
eliciting T cells (36) and the impact of minor structural
changes in the pMHC on stability (37).
T Cell Inhibitory Effects at High Peptide Concentrations. In
experiments performed with wt TCR and m6 TCR trans-
fectants, there was reduced IL-2 release at high concentra-
tions of the most potent peptides (Fig. 4). What could ac-
count for this reduction in responsiveness? One possibility
is that continued stimulation during the course of the 30-h
assay may result in extensive TCR downregulation (9). As
it is known that TCR internalization occurs constitutively,
in the absence of signaling, the loss of TCRs due to down-
modulation might yield T cells that are incapable of sus-
tained IL-2 release. Consistent with this possibility, all
transfectants that displayed lower IL-2 levels at high con-
centrations of peptides exhibited extensive loss of TCRs
(Fig. 6). T cells incubated with peptides at concentrations
that yielded optimal IL-2 release (or less potent peptides
such as p2Ca) did not exhibit this extensive TCR down-
regulation. Thus, the loss of TCRs at high pMHC density
could account for reductions in signaling and reduced IL-2
levels. Analysis of the kinetics of the down-regulation have
shown that the m6 T cell lost over 90% of surface TCR
and the wt T cell lost 80% of surface TCR in only 3 h.
Thus, despite the high affinity and slow off-rate of the m6
TCR, it undergoes rapid downregulation. The profound,
sustained, downregulation of TCRs during the entire
course of the assay could cause desensitization of the T cells
so that they are incapable of releasing IL-2.
The present data does not allow us to address the current
debate on whether nonengaged TCRs might also undergo
downregulation (28), for the following reason. We have
estimated that at QL9 concentrations above 10 nM there
are likely to be  20,000 QL9/Ld complexes per T2-Ld cell
(38). In a 3-h assay there is sufficient time for a single QL9/
Ld to undergo multiple rounds of association/dissociation
with a number of m6 TCRs (given the lifetime of dissocia-
Figure 5. Long-term stability of peptide/Ld complexes. Specific pep-
tide/Ld complexes that remained on the surface of T2-Ld at the end of a
30 h IL-2 assay were quantitated by detection with soluble m6 TCR.
T2-Ld cells were incubated with 2C TCR or m6 TCR transfectants in
the presence of various concentrations of peptides. After 30 h, cells were
harvested and peptide/Ld levels on T2-Ld were measured by staining with
soluble m6 TCR followed by F23.1–biotin/SAv:PE and flow cytometry.
Only those peptide variants (QL9, QL9-Y5, QL9-M5, and p2Ca) that
showed the highest mean fluorescence units (MFU) with m6 (see Fig. 1)
are shown. The lower level of signal with QL9-M5, compared with QL9
and QL9-Y5, is due to reduced binding affinity of QL9-M5/Ld for the
m6 TCR.
Figure 6. TCR/CD3 downregulation on TCR transfectants. 2C
TCR or m6 TCR transfectants were incubated with T2-Ld in the pres-
ence of various concentrations of peptides. After 30 h, cells were har-
vested and TCR levels were measured by flow cytometry with an anti-
CD3 Ab (2C11). Representative data from one assay is shown for the 2C
wt TCR transfectant incubated with QL9 ( ) and QL9-Y5 ( ) and the
m6 TCR transfectant incubated with QL9 ( ) and QL9-Y5 ( ).1050 High Affinity T Cell Receptors
tion of 1650 s at 25 C) yielding the observed 90% m6
TCR downregulation. Lower QL9 concentrations, where
the number of QL9/Ld complexes would be more limiting,
yielded minimal downregulation after 3 h incubation (data
not shown).
Lower peptide concentrations that yield minimal down-
regulation nevertheless generate the most productive sig-
naling and IL-2 release. Presumably, there are ligand-spe-
cific signals that dictate a TCR will be marked for internal
degradation and therefore, not recycled to the surface (29).
These signals are likely to differ from the signals initiated by
a TCR that lead to IL-2 secretion. Liu et al. (29) have sug-
gested that TCR ligation signals leading to TCR downreg-
ulation might involve dissociation of the CD3   chain. In
considering the possible differences between signals that
lead to reduced TCR recycling and IL-2 secretion, we sug-
gest that the valency state of the TCR–pMHC interaction
may provide an answer. Our thoughts in this regard were
prompted by the remarkable similarity in the “Gaussian”
distribution of peptide-induced IL-2 release (Fig. 4) and
the results of recent experiments that examined the cross-
linking of TCRs by bivalent pMHC ligands (39). In the
latter studies, reduced TCR dimerization was observed at
high concentrations of the bivalent pMHC, as monovalent
interactions predominate at these concentrations. In the
system described here, monovalent TCR interactions
could also predominate at high peptide concentrations,
leading to efficient downregulation without activation. At
high pMHC levels, each TCR could be “immobilized” in
the T cell membrane, preventing association with neigh-
boring TCR complexes. In contrast, TCR dimerization
might be achieved at lower concentrations because a li-
gated TCR–pMHC complex can associate with a mem-
brane mobile, nonligated TCR, leading to productive IL-2
release. The frequency of TCR dimerization would be dic-
tated by the stability of the pMHC and the affinity of the
TCR–pMHC. The observation that membrane mobility is
very important in TCR–pMHC binding and T cell func-
tion has been well documented (39–41) and a number of
studies have suggested that the  /  TCR may exist as a
dimer or higher order oligomer (33, 42, 43). This model
would also allow for the enhanced signaling effects of CD8
accessory molecule that could facilitate the formation of
dimeric TCR complexes through interactions with MHC
(31, 34). Interaction of a CD8 molecule in a nonligated
TCR complex with a pMHC molecule that is engaged by
a neighboring TCR could greatly facilitate the formation
of TCR dimers. Obviously, these possibilities will need to
be examined further and the TCR transfection system de-
scribed here should facilitate these studies.
Concluding Remarks. It has been suggested that the rela-
tively low affinities and fast off-rates of TCR–agonist
pMHC interactions represent an optimal window for elic-
iting T cell activity. This hypothesis has received concep-
tual support from the serial triggering model, which pro-
poses that longer lifetimes of TCR–pMHC engagement
would lead to fewer interactions of a single pMHC with
different TCRs. The early observations that TCRs lack so-
matic mutation and consequent affinity maturation (at least
not to the same level as Abs, with nanomolar affinities), also
supported the notion that T cells are not advantaged by in-
creasing the intrinsic binding affinities of their TCRs (for a
review, see reference 44). In apparent contradiction to
these predictions, we show here that T cells expressing a
high affinity TCR, produced in vitro by directed evolu-
tion, are exquisitely sensitive to low pMHC levels and that
they are fully capable of activation. We propose that the
improved T cell activity associated with longer lifetimes of
TCR engagement is inconsistent with the notion that serial
triggering is required for signaling. We believe the findings
also support the concept that TCR dimerization is impor-
tant in T cell activity and that it would be enhanced with
higher affinity TCRs.
The results imply that there must be other explanations
for why T cells have not evolved a process that yields high
affinity TCR. In fact, the relatively low affinities of TCR–
pMHC complexes are typical of most protein–protein in-
teractions involved in cell to cell contact (45). It is possible
that such affinities are necessary to maintain the full spec-
trum of functions (e.g., migration, differentiation, prolifera-
tion, etc.) that hematopoietic cells undergo. For T cells,
perhaps negative selection eliminates TCRs that might have
exhibited high affinity against a foreign peptide because
they also cross-react with self-peptides. Another possibility
is that other T cell activities, notably proliferation, might be
compromised by the presence of higher affinity TCR. It
will be important to examine this issue by introducing our
mutant TCRs into CTL lines or transgenic mice.
A further finding of the present study is that pMHC sta-
bility plays a dominant role in T cell activity. Although
many studies have shown the importance of pMHC stabil-
ity, the examples shown here illustrate how pMHC stabil-
ity can dominate the TCR–pMHC binding interaction.
Thus, we propose that apparent discrepancies between
TCR affinity and T cell activity observed in some prior
studies can be accounted for by full consideration of the
binding affinity of the peptide for MHC and the stability of
the pMHC complex at 37 C.
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